Human Genome Sciences Inc. (HGSI) (1 Viewer)
- Creatore Discussione acqua+
- Data di Inizio
coxy
coxy
scusa l'ignoranza, chi opera sul pre-market? dura fino alle 15.30?
Netzach
Forumer storico
Human Genome Sciences (HGSI) Reports Results from Long-Term Phase 2 Continuation Trial for BENLYSTA(TM)
More News related to HGSI
Human Genome Sciences (HGSI) Reports Results from Long-Term Phase 2 Continuation Trial for BENLYSTA(TM)
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
ThinkEquity Downgrades Human Genome Sciences (HGSI) to Source of Funds
Human Genome (HGSI) June volatility at 184 into Phase three data
More News related to HGSI
More News related to Corporate News
Enterra Energy (ENT) Completes Annual Renewal of Credit Facility
Genesee & Wyoming (GWR) Cuts Q2 Outlook Following May Traffic Results
Human Genome Sciences (HGSI) Reports Results from Long-Term Phase 2 Continuation Trial for BENLYSTA(TM)
Flow International (FLOW) Finalizes $40M Bank Agreement
Level 3 (LVLT) Expands Relationship with First Commercial Bank of Florida
More News related to Corporate News
June 11, 2009 8:08 AM EDT
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of results from a long-term Phase 2 continuation trial showing that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares, and was generally well tolerated through four years on treatment in combination with standard of care in patients with serologically active systemic lupus erythematosus. The results were presented today in Copenhagen at the 2009 Congress of the European League Against Rheumatism.
"Based on the results presented at EULAR 2009, the apparent durability of clinical effect and the favorable safety profile observed for belimumab suggest that belimumab has the potential to become an important new treatment for patients with SLE," said Joan T. Merrill, M.D., a study investigator, Program Chair, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, and Professor, Department of Medicine, University of Oklahoma Health Sciences Center.
SLE is a chronic, life-threatening autoimmune disease. It is estimated that approximately 1.5 million people in the United States and approximately 5 million worldwide suffer from various forms of lupus, including SLE.
More from the release.
More News related to HGSI
Human Genome Sciences (HGSI) Reports Results from Long-Term Phase 2 Continuation Trial for BENLYSTA(TM)
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
ThinkEquity Downgrades Human Genome Sciences (HGSI) to Source of Funds
Human Genome (HGSI) June volatility at 184 into Phase three data
More News related to HGSI
More News related to Corporate News
Enterra Energy (ENT) Completes Annual Renewal of Credit Facility
Genesee & Wyoming (GWR) Cuts Q2 Outlook Following May Traffic Results
Human Genome Sciences (HGSI) Reports Results from Long-Term Phase 2 Continuation Trial for BENLYSTA(TM)
Flow International (FLOW) Finalizes $40M Bank Agreement
Level 3 (LVLT) Expands Relationship with First Commercial Bank of Florida
More News related to Corporate News
June 11, 2009 8:08 AM EDT
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of results from a long-term Phase 2 continuation trial showing that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares, and was generally well tolerated through four years on treatment in combination with standard of care in patients with serologically active systemic lupus erythematosus. The results were presented today in Copenhagen at the 2009 Congress of the European League Against Rheumatism.
"Based on the results presented at EULAR 2009, the apparent durability of clinical effect and the favorable safety profile observed for belimumab suggest that belimumab has the potential to become an important new treatment for patients with SLE," said Joan T. Merrill, M.D., a study investigator, Program Chair, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, and Professor, Department of Medicine, University of Oklahoma Health Sciences Center.
SLE is a chronic, life-threatening autoimmune disease. It is estimated that approximately 1.5 million people in the United States and approximately 5 million worldwide suffer from various forms of lupus, including SLE.
More from the release.
Netzach
Forumer storico
coxy
coxy
1. segnalato da acqua+ come titolo di spessore in epoca ancestrale (per i traders).
2. indicato come progetto complessivo basato su anticorpi monoclonali o fusione
ad aldumina (human) per migliorare principi attivi già riconosciuti (mutatis mutandis strategia simile a quella della nicox, ma biotecnologica e non di chimica farmaceutica).
3. tutto noto eppure
silenzio.
Mi permetto di far notare che Un 70% di possibilità di contribuire ad alleviare l'esistenza a malati di SLE è cosa notevole, perchè se va male questa volta (e non credo), la prossima si riuscirà. Accoppiata di valore e valsente. forse ma dobbiamo attendere pochi mesi.
2. indicato come progetto complessivo basato su anticorpi monoclonali o fusione
ad aldumina (human) per migliorare principi attivi già riconosciuti (mutatis mutandis strategia simile a quella della nicox, ma biotecnologica e non di chimica farmaceutica).
3. tutto noto eppure
silenzio.
Mi permetto di far notare che Un 70% di possibilità di contribuire ad alleviare l'esistenza a malati di SLE è cosa notevole, perchè se va male questa volta (e non credo), la prossima si riuscirà. Accoppiata di valore e valsente. forse ma dobbiamo attendere pochi mesi.
